Literature DB >> 11932419

Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

Joshua Arrington1, Ralph P Braun, Lichun Dong, Deborah H Fuller, Michael D Macklin, Scott W Umlauf, Sarah J Wagner, Mary S Wu, Lendon G Payne, Joel R Haynes.   

Abstract

Two plasmid vectors encoding the A and B subunits of cholera toxin (CT) and two additional vectors encoding the A and B subunits of the Escherichia coli heat-labile enterotoxin (LT) were evaluated for their ability to serve as genetic adjuvants for particle-mediated DNA vaccines administered to the epidermis of laboratory animals. Both the CT and the LT vectors strongly augmented Th1 cytokine responses (gamma interferon [IFN-gamma]) to multiple viral antigens when codelivered with DNA vaccines. In addition, Th2 cytokine responses (interleukin 4 [IL-4]) were also augmented by both sets of vectors, with the effects of the LT vectors on IL-4 responses being more antigen dependent. The activities of both sets of vectors on antibody responses were antigen dependent and ranged from no effect to sharp reductions in the immunoglobulin G1 (IgG1)-to-IgG2a ratios. Overall, the LT vectors exhibited stronger adjuvant effects in terms of T-cell responses than did the CT vectors, and this was correlated with the induction of greater levels of cyclic AMP by the LT vectors following vector transfection into cultured cells. The adjuvant effects observed in vivo were due to the biological effects of the encoded proteins and not due to CpG motifs in the bacterial genes. Interestingly, the individual LT A and B subunit vectors exhibited partial adjuvant activity that was strongly influenced by the presence or absence of signal peptide coding sequences directing the encoded subunit to either intracellular or extracellular locations. Particle-mediated delivery of either the CT or LT adjuvant vectors in rodents and domestic pigs was well tolerated, suggesting that bacterial toxin-based genetic adjuvants may be a safe and effective strategy to enhance the potency of both prophylactic and therapeutic DNA vaccines for the induction of strong cellular immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932419      PMCID: PMC155070          DOI: 10.1128/jvi.76.9.4536-4546.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Genetically derived toxoids for use as vaccines and adjuvants.

Authors:  G Del Giudice; R Rappuoli
Journal:  Vaccine       Date:  1999-10-01       Impact factor: 3.641

2.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

Authors:  T P Le; K M Coonan; R C Hedstrom; Y Charoenvit; M Sedegah; J E Epstein; S Kumar; R Wang; D L Doolan; J D Maguire; S E Parker; P Hobart; J Norman; S L Hoffman
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

3.  Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming.

Authors:  M C Gagliardi; F Sallusto; M Marinaro; A Langenkamp; A Lanzavecchia; M T De Magistris
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

4.  Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.

Authors:  J D Boyer; A D Cohen; S Vogt; K Schumann; B Nath; L Ahn; K Lacy; M L Bagarazzi; T J Higgins; Y Baine; R B Ciccarelli; R S Ginsberg; R R MacGregor; D B Weiner
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

5.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.

Authors:  M J Roy; M S Wu; L J Barr; J T Fuller; L G Tussey; S Speller; J Culp; J K Burkholder; W F Swain; R M Dixon; G Widera; R Vessey; A King; G Ogg; A Gallimore; J R Haynes; D Heydenburg Fuller
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

6.  Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.

Authors:  M Martin; D J Metzger; S M Michalek; T D Connell; M W Russell
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

7.  Transcutaneous immunization: a human vaccine delivery strategy using a patch.

Authors:  G M Glenn; D N Taylor; X Li; S Frankel; A Montemarano; C R Alving
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

8.  The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity.

Authors:  E Y Enioutina; D Visic; R A Daynes
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

9.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.

Authors:  T Scharton-Kersten; J m Yu; R Vassell; D O'Hagan; C R Alving; G M Glenn
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 10.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.

Authors:  R Rappuoli; M Pizza; G Douce; G Dougan
Journal:  Immunol Today       Date:  1999-11
View more
  23 in total

1.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.

Authors:  Tetsuya Harakuni; Hideki Sugawa; Ai Komesu; Masayuki Tadano; Takeshi Arakawa
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Optimized FaeG expression and a thermolabile enterotoxin DNA adjuvant enhance priming of an intestinal immune response by an FaeG DNA vaccine in pigs.

Authors:  V Melkebeek; E Sonck; F Verdonck; B M Goddeeris; E Cox
Journal:  Clin Vaccine Immunol       Date:  2006-11-15

5.  Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Authors:  Kenneth C Bagley; George K Lewis; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

6.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

7.  Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease.

Authors:  Arlene I Ramsingh; Kevin Manley; Yinghui Rong; Andrew Reilly; Anne Messer
Journal:  Hum Mol Genet       Date:  2015-08-24       Impact factor: 6.150

8.  Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.

Authors:  Deborah Heydenburg Fuller; Tim Shipley; Todd M Allen; James T Fuller; Mary S Wu; Helen Horton; Nancy Wilson; Georg Widera; David I Watkins
Journal:  Virology       Date:  2007-04-11       Impact factor: 3.616

9.  RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

Authors:  Hongzhuan Wu; Vida A Dennis; Shreekumar R Pillai; Shree R Singh
Journal:  Virus Res       Date:  2009-06-21       Impact factor: 3.303

10.  Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization.

Authors:  Yihang Li; Sudhir K Ahluwalia; Alexandre Borovkov; Andrey Loskutov; Chengming Wang; Dongya Gao; Anil Poudel; Kathryn F Sykes; Bernhard Kaltenboeck
Journal:  Vaccine       Date:  2009-12-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.